MARKSANS Q2 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹720.4 Cr
verified against source
Revenue YoY
12.2%
reported change
EBITDA
₹144.5 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Marksans Pharma delivered a strong Q2 FY26 with revenue of Rs 720.4 crore (up 12.2% YoY), recovering from a softer Q1. US/North America drove growth at Rs 387 crore (27% YoY) on new launches in digestive health and pain management. EBITDA margin improved 391bps sequentially to 20.1%, though down 108bps YoY due to UK pricing pressure and headcount addition at the Goa facility. PAT grew modest 1.4% to Rs 99.1 crore. Management guided for sustained north of 20% EBITDA margins and targets Rs 3,000 crore revenue by FY28, scaling to Rs 5,000 crore in 5-7 years. Key growth vectors include German market entry in Q1 FY26, new UK product approvals (3 MHRA authorizations received), and capacity expansion at the old plant to 1.3 billion tablets. Working capital normalization to 120-130 days is expected from Q1 FY27 as inventory levels built during tariff uncertainty ease. Risk: UK pricing pressure remains intense and US tariff uncertainty, while partially resolved, still warrants monitoring.
Colored figures show movement against the previous available record.
Guidance to track
- Management confirmed targeting Rs 3,000 crore revenue in the next 2-3 years, implying a near doubling from current levels driven by US growth and new market entries.
- Long-term goal of Rs 5,000 crore revenue by approximately FY30-FY32, requiring new infrastructure investment and geographic expansion.
- Management expects margins to sustain at 20% or better going forward, with Q3 expected to be similar to Q2 on seasonal basis.
- Organic market entry in Germany with employee hiring and office setup in progress. Full operations expected from Q1 FY26 with revenue contribution from H2 FY26.
Risks flagged
- The UK market continues to face significant pricing erosion and pressure. Management acknowledged this is an ongoing challenge but expects new product approvals to provide bottom-line support over time.
- While 3 MHRA approvals were received, management indicated that meaningful revenue impact from UK high-value product launches will only start in Q3 2026, suggesting continued margin pressure in near term.
- Although management expressed confidence that pharma tariffs are off the table, this was described as emerging clarity in the last 1-1.5 months. The reversibility risk remains given political dynamics.
- The company holds 5-6 months of inventory (vs typical 2-3 months) and management expects normalization only from Q1 FY27, tying up significant capital for multiple quarters.
Key quotes
- The uncertainty has diluted to a great level because the current administration has made it clear that pharma tariffs are not going to come on pharmaceutical products.
- We are still targeting 300 million order book in a couple of years... as in by FY28. Yeah, we hope.
- It's a very reasonable and fair assumption [EBITDA margins] may be slightly better but north of 20%... from a safe point of view 19 to 20% is very reasonable.
Research modules